Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials
Revance Therapeutics has released late-stage data for a wrinkle-reducing drug that rivals Botox. If it reaches the market, the Bay Area biotech plans to go head-to-head with the giant in this field: Allergan.
Revance $RVNC reported on two Phase III clinical trials of its drug, an injectable botulinum toxin coined RT002. The drug was tested against frown lines — those wrinkles that show up between your eyebrows. RT002 lasted for six months, while Botox generally only lasts for three to four months. The study met its primary and secondary endpoints in the two Phase III trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.